Type II photodynamic therapy (PDT) is used for cancer treatment based on the combined action of a photosensitizer, a special wavelength of light, oxygen ( 
O2]) before and after the treatment as well as photosensitizer concentration and hemodynamic parameters such as blood flow during PDT has been reported. Simulation of these variations is valuable, as it would be a means for the rapid assessment of treatment effect. A mathematical model has been previously developed to incorporate the diffusion equation for light transport in tissue and the macroscopic kinetic equations for simulation of [ 
INTRODUCTION
Type II photodynamic therapy (PDT) requires three key components of drug, light, and oxygen ( 3 O2), which interact on time scales relevant to a single treatment to generate singlet oxygen ( 1 O2). [1] [2] [3] [4] Although an understanding of the biology of PDT has expanded tremendously over the past few years, it is still a challenge to match the extent of PDT effects to the extent of the disease being treated in the clinic. To quantitatively account for the biological damage done by PDT, it is suggested to account for 1 O2 production during PDT. 5, 6 However, the weak and short lifetime of the luminescence signals due to rapid reactions of 1 O2 in biological environments is a major obstacle to use luminescence detection methods in clinical applications. 7, 8 In this study, a macroscopic model, 5, 6, 9, 10 which incorporates a complete set of kinetic PDT equations and information obtained from the explicit dosimetry of the light fluence rate (ϕ), initial photosensitizer and oxygen ([³O₂]₀) concentration and tissue optical properties is used to calculate the temporal changes of reacted singlet oxygen concentration ([ 1 O2]rx) during PDT. As the generation of 1 O2 depends in part on the availability of 3 O2 in the target tissue, knowing the level of tissue oxygenation before, during, and after PDT is important in understanding the basic physiological mechanism and the light dosimetry. 11, 12 Oxygen delivery is dependent on the metabolic requirements and functional status of each organ. During PDT, both photochemical consumption of 3 O2 and microvascular shutdown can lead to depletion of molecular 3 O2. Therefore, there is an immediate need for additional 3 O2 in tissue, which might be accomplished by increasing blood flow. 13 However, if tissue oxygenation is reduced to levels insufficient for further tissue damage, this influences the treatment outcome. In order to consider the blood flow changes during PDT, a time dependent oxygen supply rate, g, has been introduced in our model 14 based on the data published for in vivo blood flow changes in mice models. 13 To assess the efficacy of our simulations, the temporal changes of [ 
Measurements of the photosensitizer concentration prior and after the photodynamic therapy
In order to determine the HPPH concentration in the tumor, a catheter was inserted into the center of the tumor. Then, a single side-cut fiber connected to a dichroic filter was placed into the catheter, which served as both an excitation source and a detector to record the interstitial HPPH fluorescence emission spectrum along the catheter axis. The photosensitizer was excited using a 405 nm diode laser. The raw spectrum was fitted to the basis spectrum of HPPH and autofluorescence in the absence of HPPH using singular value decomposition (SVD). The attenuation of the photosensitizer fluorescence signal due to the light absorption and scattering by tissue was corrected by applying a correction factor, which is a function of tissue optical absorption (µa) and scattering (µ's) coefficients. Then, the spectra were compared with those measured in phantoms of known HPPH concentration to extract the in vivo drug concentration. More detailed description of the measurements and calculations has been published previously.
16, 17

Measurements of the tissue oxygenation prior, during and after the photodynamic therapy
Following the HPPH drug-light interval of 24 h, PDT was performed and the tissue oxygenation was measured prior, during, and post treatment. For direct measurements of the tissue oxygen saturation of hemoglobin pO2, the point measurements were made each 3 min using OxyLite 1 Channel tissue pO2 monitor (OXFORD OPTRONIX). Based on our simulations, the tissue oxygenation decreases dramatically at the first 5 min of the PDT; the [³O₂] drop varies with the light delivery regimen and [³O₂]₀. In order to measure this [³O₂] drop in mice tissue, the point measurements were performed each 1 min at the first 5 min of the treatment. As the OxyLite probe is a phosphorescence-based probe, the PDT excitation light was paused for each measurement. The mice were treated on a heated water pad under anesthesia in all studies. Then, [³O₂] was calculated by multiplying the measured pO2 with ³O₂ solubility in tissue, which is 1.295 µM/mmHg. 
Photodynamic equations
A set of equations is produced by simplifying and combining the energy transfer processes in PDT to describe the changes of [ These equations are dependent on various parameters such as the ground state photosensitizer (S0), light source (s), µa, µ's and photosensitizer photochemical parameters: 
Simulation of blood flow changes during PDT
Oxygen delivery is dependent on the metabolic requirements and functional status of each organ. Due to the PDT oxygen consumption, there is an immediate need for additional 3 O2 in tissue, which is accomplished by increasing blood flow. The change of the blood flow during PDT was simulated in our macroscopic model by making g to be time dependent. The g function was obtained from the best fit to the data presented in Ref. 13 
where, t' = (t -750)/632.1 is normalized by mean 750 and standard deviation 632.1 (with 95% confidence bounds). Table 1 . Table 1 . Tissue optical properties, initial oxygen and HPPH concentrations as well as photochemical parameters used in the simulations.
RESULTS
RIF
In-air ϕ The spatial distribution of ϕ in the tumor calculated by using the diffusion equation (Eq. (1)) has been shown in Fig. 1(a) . Fig. 1(b) shows the temporal changes of the normalized g (g/g0) obtained from Eq. (5). The changes of photosensitizer concentration versus total fluence calculated from Eq. (3) can be found in Fig. 1(c) . 
DISCUSSIONS
The relationship between tissue oxygenation, blood flow variation, and PDT effect is complex, and remarkably few studies have directly correlated ³O₂ and blood flow changes during PDT with the final biological effect. 13, 14 The photochemical 3 O2 consumption and its importance for PDT were first demonstrated experimentally in multi-cell tumor spheroids, 12 which does not account for the blood flow changes during the treatment. To our knowledge, there is no real time monitoring to ensure adequate oxygenation at strategic points in tumor tissues during PDT. In this study, we measured the oxygen consumption during PDT of RIF tumors in five C3H mice administered with HPPH. Based on the results, tumor oxygen status before PDT, which has been measured to be 20.5 ± 2.4 µM, markedly deteriorated at the first 400 s of the treatment; the drop was 94 ± 6.9 percent of the pre-treatment oxygenation. After this immediate drop, an increase in the tissue oxygenation occurred, which reached 17.77 ± 3.42 µM by the end of the treatment. In all PDT treatments, the irradiation was performed with an in-air fluence of 80 mW/cm 2 and a total energy of 160 J/cm 2 . In order to evaluate our macroscopic model, the temporal changes of [³O₂] was also calculated using the same treatment condition, initial photosensitizer, and [³O₂]0. In our model, the blood flow changes during PDT was simulated by making g to be time dependent based on the best fit to the in vivo data presented in Ref. 13 for Photofrin-mediated PDT; to our knowledge there is no published data for the blood flow changes during the HPPH-mediated PDT. Although both macroscopic models with and without blood flow changes show a reasonably good agreement with the measurements, a peak measured in the region of 700-1200 s could not be calculated with our simulations. As different photosensitizers might impact the blood flow differently, we think [³O₂] peak at 700-1200 s might be due to a blood flow increase during the HPPH-PDT that present for the case for Photofrin-PDT. However, detailed studies are required to investigate the blood flow changes during HPPH-PDT and its impact on the [³O₂] consumption. The amount of [ The mean [³O₂] drops to 33.9 ± 12.0 percent of the pretreatment level in complement-proficient C57BL/6 (B6) hosts bearing lewis lung carcinoma and MCA205 fibrosarcoma following Photofrin-PDT. 18 The drop in the mean [³O₂] following benzoporphyrin derivative (BPD)-PDT in B6 is reported to be 53.2 ± 19.1 percent of the pretreatment level at the same tumor type. 18 Tumor oxygenation before the treatment (3.25-26 µM) was not significantly affected with B6 mice administered with Photofrin or BPD in the absence of light exposure or by tumor light treatment alone. 18 This information has been used in our simulations to investigate the temporal changes of [³O₂] during Photofrin-PDT and their effect on [ 1 O₂]rx. We also studied the impact of the blood flow changes during PDT on our simulations. Table 2 shows the tissue optical properties, g0, photochemical parameters, [³O₂]₀, drug concentration and in-air fluence rate and fluence used in our simulation for Photofrin-PDT. 6 Table 2 . Tissue optical properties, initial oxygen and Photofrin concentrations as well as photochemical parameters and the treatment protocol used in the simulations. 6, 15 Sensitizer
In-air ϕ (mW/cm with excellent agreement the changes in ³O₂ consumption that have been measured. Fig. 3 
CONCLUSION
In PDT, the spatial distribution of light in tissue is determined by the light source characteristics and the tissue optical properties. 4, 19 The tissue optical properties, in turn, are affected by the concentration of photosensitizer, as well as the concentration and oxygenation state of the blood in the tissue. Therefore, tissue optical properties, the variability in time and/or space of ground-state [ 3 O2], sensitizer availability and light delivery to the treatment area during typical therapy should be incorporated in PDT dosimetry. 20 To quantitatively account for the biological damage done by PDT, some researchers are considering the measurement of a quantity that depends on all, or at least most, of the above factors. 5, 6 The measurement of [ 1 O2]rx is one of the suggestions that could allow for the determination of the biological response that a specific treatment protocol would evoke. As it is extremely difficult to monitor [ 
